Ignite Creation Date:
2025-12-24 @ 7:38 PM
Ignite Modification Date:
2026-01-01 @ 12:48 PM
Study NCT ID:
NCT06690203
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
2024-11-15
First Post:
2024-10-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Evaluation of the Safety and Clinical Efficacy of NRICM102 in Patients With Chronic Lower Respiratory Tract Diseases
Sponsor:
Taichung Veterans General Hospital
Organization:
Study Overview
Official Title:
TaichungVGH Taichung Veterans General Hospital
Status:
ENROLLING_BY_INVITATION
Status Verified Date:
2024-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is to assess safety and efficacy of NRICM102 decoction in participants with CLRD. This study will be conducted in 70 participants. The study consists of 3 periods: a 4-week screening period, a treatment period for at least 12 weeks up to 24 weeks.
Detailed Description:
* Investigational product(s)： NRICM102 Decoction
* Development Phase: A real-world Prospective study
* Study Design：
1. Experimental Group: Standard of care combined NRICM102 for 12weeks
2. Blinding：Open
3. Randomization: No
4. Parallel design : Not applicable
5. Treatment Period：12 to 24 weeks by groups
6. Study Period: From 01/07/2024 to 31/12/2025
7. Dose adjustment： Not applicable
8. Study location： Single
* Study Procedures： This study is to assess safety and efficacy of NRICM102 decoction in participants with CLRD. This study will be conducted in 70 participants. The study consists of 3 periods: a 4-week screening period, a treatment period for at least 12 weeks up to 24 weeks. In principle, the two groups are divided into 1:1. The study group period is divided into a continuous treatment group and a discontinued treatment group. The purpose is to evaluate the drug safety of continuous treatment for 24 weeks and the similarities and differences in the physiological assessment of the subjects between the two groups, so as to serve as a reference for the design of a combined treatment program of traditional Chinese and Western medicine for chronic respiratory diseases. Since subjects may terminate early during the taking period, we also designed an evaluation time point, and also conducted an evaluation at the early end of time (EOS).
* Statistical Methods：
1. Main study Hypothesis：Not applicable
2. Estimated Sample Size：This study will be conducted in 70 participants. 50 subjects can be evaluated in the trial.
3. Efficacy assessment group：Intent-to-treat (ITT)
4. Interim analysis：No
5. Statistical methods： All participants who have been randomized to study intervention and who have received at least one dose of study intervention will be included in the Efficacy Analysis Set. The Safety Analysis Set is defined as all participants who have been randomized to study intervention.
All results will be presented by treatment with descriptive statistics appropriate to the nature of the variables. Demographic and baseline characteristics will be presented as follows; for continuous variables, the number of non-missing observations, mean, standard deviation (SD), standard error (SE) of the mean, 95% confidence interval (CI) of the mean (except safety data), median, first and third quartiles, minimum and maximum, will be presented; for categorical variables: counts (n) and percentages (%) (where specified) will be presented. These summaries will be provided by time point of assessment as appropriate.
Details on the handling of missing data for the safety or efficacy analyses will be provided.
1. Safety will be assessed by descriptive analysis of vital signs, ECGs, laboratory assessments and AEs reported.
2. Change from baseline in health related QOL questionnaires ACT, ACQ-5, CAT, SGRQ and mMRC, spirometry and walking distance of visit and average over the treatment period will be reported, and subgroup analysis in CLRT will be provided at Weeks 4, 12, 24 and average over the treatment period.
* 6\. Handling of Missing Data： The missing data will not be included in the analysis.
* Development Phase: A real-world Prospective study
* Study Design：
1. Experimental Group: Standard of care combined NRICM102 for 12weeks
2. Blinding：Open
3. Randomization: No
4. Parallel design : Not applicable
5. Treatment Period：12 to 24 weeks by groups
6. Study Period: From 01/07/2024 to 31/12/2025
7. Dose adjustment： Not applicable
8. Study location： Single
* Study Procedures： This study is to assess safety and efficacy of NRICM102 decoction in participants with CLRD. This study will be conducted in 70 participants. The study consists of 3 periods: a 4-week screening period, a treatment period for at least 12 weeks up to 24 weeks. In principle, the two groups are divided into 1:1. The study group period is divided into a continuous treatment group and a discontinued treatment group. The purpose is to evaluate the drug safety of continuous treatment for 24 weeks and the similarities and differences in the physiological assessment of the subjects between the two groups, so as to serve as a reference for the design of a combined treatment program of traditional Chinese and Western medicine for chronic respiratory diseases. Since subjects may terminate early during the taking period, we also designed an evaluation time point, and also conducted an evaluation at the early end of time (EOS).
* Statistical Methods：
1. Main study Hypothesis：Not applicable
2. Estimated Sample Size：This study will be conducted in 70 participants. 50 subjects can be evaluated in the trial.
3. Efficacy assessment group：Intent-to-treat (ITT)
4. Interim analysis：No
5. Statistical methods： All participants who have been randomized to study intervention and who have received at least one dose of study intervention will be included in the Efficacy Analysis Set. The Safety Analysis Set is defined as all participants who have been randomized to study intervention.
All results will be presented by treatment with descriptive statistics appropriate to the nature of the variables. Demographic and baseline characteristics will be presented as follows; for continuous variables, the number of non-missing observations, mean, standard deviation (SD), standard error (SE) of the mean, 95% confidence interval (CI) of the mean (except safety data), median, first and third quartiles, minimum and maximum, will be presented; for categorical variables: counts (n) and percentages (%) (where specified) will be presented. These summaries will be provided by time point of assessment as appropriate.
Details on the handling of missing data for the safety or efficacy analyses will be provided.
1. Safety will be assessed by descriptive analysis of vital signs, ECGs, laboratory assessments and AEs reported.
2. Change from baseline in health related QOL questionnaires ACT, ACQ-5, CAT, SGRQ and mMRC, spirometry and walking distance of visit and average over the treatment period will be reported, and subgroup analysis in CLRT will be provided at Weeks 4, 12, 24 and average over the treatment period.
* 6\. Handling of Missing Data： The missing data will not be included in the analysis.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: